Store

Home | Store | Cell Therapy and Gene Therapy Markets, 2021-2031

Cell Therapy and Gene Therapy Markets, 2021-2031

Publication Date: February 17, 2022

LICENSE

Clear

SKU: 22-021

Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Life Science, Oncology and Cancer

Pages: 270

SKU: 22-021

Stay ahead in the rapidly evolving cell and gene therapy (CGT) industry with our comprehensive market analysis from Kalorama Information. Cell Therapy and Gene Therapy Markets, 2021-2031 covers market segments, disease epidemiology, and competitive landscapes, providing valuable insights for stakeholders.

Market Segmentation and Analysis:

Product Segments: Detailed market estimates and forecasts for dermatological, cardiovascular-blood, oncology, ophthalmic, musculoskeletal, and other conditions.
Method Segments: Analysis of cell therapy, gene therapy, and the total market.
Geographical Regions: Market breakdowns for the United States, Europe/EU, and other regions.
U.S. Market: In-depth analysis of product segments, including dermatological, cardiovascular-blood, oncology, ophthalmic, musculoskeletal, and other conditions.
Market Distribution: Product segment distributions for the U.S., Europe, and other countries.
Leading Competitors: Sales estimates and market share analysis for top companies.

Scope:

The report provides a thorough examination of cell and gene therapy markets by condition/disorder, including:

Dermatology: Market analysis by product type (stem cells, skin cells) and general indication (wound healing/treatment, other indications).
Cardiovascular and Blood Disorders: Market breakdown by product type (stem cells, gene therapy) and general indication (cardiac, vascular, blood disorders).
Oncology: Detailed market analysis by product type (CAR-T, cell immunotherapy) and general indication (blood cancers, prostate cancer).
Ophthalmic Conditions: Market segmentation by product type (stem cells, gene therapy) and region.
Musculoskeletal Conditions: Market overview by product type and general indication (cartilage and bone defect repair).
Other Conditions: Comprehensive market analysis by product type and region.

Why This Report is Essential:

Market Insights: Gain a deep understanding of the CGT market, including trends in research and development, regional market summaries, and competitor analyses.
Strategic Planning: Utilize detailed forecasts and sales estimates to inform strategic decisions and identify market opportunities.
Competitive Analysis: Stay informed about leading providers and their market positions.

Table: Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2021 and Projected 2031
($ millions)

Product Type	2021 Sales	2031 Sales
Stem cells	$XX Million	$XX Million
Skin cells	$XX Million	$XX Million
Gene/gene-modified cell therapy	$XX Million	$XX Million

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2021-2031

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

Cell Therapy

Table 2-1: Adult vs. Embryonic Stem Cells

Gene Therapy

Table 2-2: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

Table 2-3: Selected Examples of Viruses in Gene Therapy
Figure 2-1: Viral Vector Use in Commercialized Cell and Gene Therapies

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

Table 2-4: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

Table 2-5: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Figure 2-2: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Table 2-6: Selected Recent Viral Vector Company Expansion

Cost

Reimbursement

Logistics

Mergers and Acquisitions

Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Partnerships, Agreements and Collaborations

Table 2-8: Selected Company Partnerships, Agreements and Collaborations in the Cell and Gene Therapy Market

Financing and Funding Deals

Table 2-9: Recent Cell and Gene Therapy Recent Financing Deals

Regulatory Developments

Figure 2-3: FDA Cell & Gene Therapy Percent of Projects with Orphan Drug and/or Fast Track Status

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

Table 2-10: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country

Individualized Gene Therapy Approval Process

Development and Pipeline Overview

Development Progress

Figure 2-4: Global Cell and Gene Therapy Development Progress (phase I through phase III), as of January 2022
Figure 2-5: Global Cell and Gene Therapy Development Progress by Phase, as of January 2022

Development by Condition/Disorder

Figure 2-6: Global Development of Cell and Gene Therapies by Target

Global Participation in Cell and Gene Therapy Development

Figure 2-7: Global Development Activity of Cell and Gene Therapies by Country, as of January 2022

Phase III Development

Table 2-11: Phase III Development ¾ Cell and Gene Therapies, Select Projects
Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)

End User

Hospitals

Research Institutes

Wound Care Centers

Cancer Centers

Chapter 3: Cell and Gene Therapy Markets in Dermatology

Overview

Table 3-1: Wound Prevalence by Type

Market Outlook

Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2021-2031 ($ millions)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 3-4: Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

Table 3-5: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 3-6: Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

Table 3-7: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 3-3: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Dermatology Cell and Gene Therapy Market by Indication

Table 3-8: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)

Regional Market Summary

Figure 3-4: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 3-9: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
Figure: 3-5: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

Table 3-10: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2021-2031, ($ millions)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

Cord Blood Products

Table 4-1: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)

Regional Market Summary

Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
Figure: 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

Chapter 5: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

Table 5-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

Figure 5-1: Estimated Number of New Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
Figure 5-2: Incidence of Cancer by Type, 2020
Figure 5-3: Distribution of Cancer Incidence by Type, 2020

Market Outlook

Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2021-2031 ($ millions)

Principal Products

Abecma

APCeden

Breyanzi

CreaVax-RCC

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Tecartus

Yescarta

Table 5-2: Cell and Gene Therapy in Oncology
Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

Table 5-3: Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 5-4: Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, January 2022 Data (Phase I through Phase III)

Phase III Development

Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020

Market Breakdown of Cell and Gene Therapies

Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 5-7: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

Table 5-8: Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 5-8: Oncology Cell and Gene Therapy Market by General Indication (leukemia, lymphoma, undefined blood cancer, prostate cancer, melanoma, multiple myeloma, other cancers), Estimated 2021 (%)

Regional Market Summary

Figure 5-9: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
Figure: 5-10: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions

Overview

Market Outlook

Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2021-2031 ($ millions)

Principal Products

Holoclar

Luxturna

Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions

Trends in Research and Development

Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 6-2: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
Figure: 6-3: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2021-2031 ($ millions)

Principal Products

AlloStem

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
Figure 7-2: Musculoskeletal Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

Table 7-4: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022

Market Breakdown of Cell and Gene Therapies

Table 7-5: Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

Table 7-6: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
Figure 7-3: Musculoskeletal Cell and Gene Therapy Market by General Indication (cartilage treatment, bone treatment and other indications), Estimated 2021 (%)

Regional Market Summary

Figure 7-4: Musculoskeletal Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 7-7: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
Figure: 7-5: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

Table 7-8: Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Chapter 8: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

Figure 8-1: Cell and Gene Therapy Markets in Neurological-Related Conditions, 2021-2031, ($ millions)

Principal Products

Libmeldy

NeuroNata-R

Onpattro

SKYSONA

Stemirac

Zolgensma

Table 8-1: Cell and Gene Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

Table 8-2: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 8-3: Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

Table 8-4: Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
Figure 8-2: Neurological Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

Table 8-5: Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
Figure 8-3: Neurological Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

Table 8-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Chapter 9: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

Figure 9-1: Cell and Gene Therapy Markets in Other Conditions, 2021-2031, ($ millions)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Oxlumo

Rethymic

Ryplazim

Strimvelis

Temcell/Prochymal/Ryoncil

Table 9-1: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

Table 9-2: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
Figure 9-2: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

Table 9-3: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
Figure 9-3: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

Chapter 10: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

Table 10-1: Global Population, through 2050 (population in millions)
Figure 10-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

Table 10-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

Table 10-3: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
Figure 10-2: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031
Figure 10-3: Cell and Gene Therapy Market, Distribution of Sales by Product Segment, 2021

Cell vs. Gene Therapy Markets

Table 10-4: Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
Figure 10-4: Cell and Gene Therapy Market, Distribution of Sales by Method, 2021

Regional Market Overview

Table 10-5: Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)

United States

Table 10-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions)
Figure 10-5: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

Table 10-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
Figure 10-6: Europe Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

Table 10-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
Figure 10-7: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

Table 10-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
Figure 10-8: Cell and Gene Therapy Market Share Estimates, 2021

Chapter 11: Market Participants

Leading Influencers

Advaxis, Inc. (Biosight Therapeutics)

Table 11-1: Advaxis Corporate Summary

Company Summary

Products

AlloSource

Table 11-2: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

Table 11-3: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

Table 11-4: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

Table 11-5: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

Table 11-6: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

Table 11-7: Atara Biotherapeutics Corporate Summary

Company Summary

Products

Athersys, Inc

Table 11-8: Athersys Corporate Summary

Company Summary

Products

BioCardia

Table 11-9: BioCardia Summary

Company Summary

Products

Biogen, Inc.

Table 11-10: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

Table 11-11: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

Table 11-12: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

Table 11-13: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

Table 11-14: Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Caladrius Biosciences

Table 11-15: Caladrius Biosciences Corporate Summary

Company Summary

Products

Candel Therapeutics

Table 11-16: Candel Therapeutics Corporate Summary

Company Summary

Products

Castle Creek Biosciences

Table 11-17: Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

Table 11-18: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

Table 11-19: Cook Myosite Corporate Summary

Company Summary

Products

Cytori Therapeutics, Inc

Table 11-20: Cytori Therapeutics Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals LLC

Table 11-21: Dendreon Corporate Summary

Company Summary

Products

FerGene, Inc/Ferring Pharmaceuticals

Table 11-22: FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

Table 11-23: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

Table 11-24: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

Table 11-25: Gilead Sciences Corporate Summary

Company Summary

Products

Gradalis, Inc

Table 11-26: Gradalis Corporate Summary

Company Summary

Products

Helixmith

Table 11-27: Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

Table 11-28: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products

Kiadis Pharma B.V. (Sanofi)

Table 11-29: Kiadis Pharma Corporate Summary

Company Summary

Products

Medeor Therapeutics

Table 11-30: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

Table 11-31: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

Table 11-32: MeiraGTxCorporate Summary

Company Summary

Products

Merck & Co., Inc.

Table 11-33: Merck & Co. Corporate Summary

Company Summary

Products

Mesoblast Ltd.

Table 11-34: Mesoblast Corporate Summary

Company Summary

Products

Neurotech Pharmaceuticals. Inc.

Table 11-35: Neurotech Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

Table 11-36: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

Table 11-37: Novartis Corporate Summary

Company Summary

Products

NuVasive Biologics

Table 11-38: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

Table 11-39: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

Table 11-40: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

Table 11-41: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc.( part of Smith & Nephew)

Table 11-42: Osiris Corporate Summary

Company Summary

Products

Pharmicell

Table 11-43: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

Table 11-44: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

Table 11-45: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

Table 11-46: Sanofi Corporate Summary

Company Summary

Products

Sotio a.s.

Table 11-47: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

Table 11-48: Spark Therapeutics Corporate Summary

Company Summary

Products

Tessa Therapeutics, Ltd.

Table 11-49: Tessa Therapeutics Corporate Summary

Company Summary

Products

uniQure N.V.

Table 11-50: UniQure Corporate Summary

Company Summary

Products

VBL Therapeutics (Vascular Biogenics Ltd.)

Table 11-51: VBL Therapeutics Corporate Summary

Company Summary

Products

Vericel Corporation

Table 11-52: Vericel Corporate Summary

Company Summary

Products

Related products

COVID-19 Testing Markets, 2023

May 18, 2023

As the COVID-19 pandemic evolves into an endemic phase, the landscape of COVID-19 testing is changing rapidly. Kalorama Information’s COVID-19 Testing Markets, 2023 report provides crucial insights into this shifting market, answering key questions and providing valuable market sizing and estimates.

Key Insights Provided:

Market impacts and trends in the evolving COVID-19 testing…

$4,000.00 – $6,000.00

Clinical Laboratory Services Market, 8th Edition

May 18, 2023

Laboratories are the workhorse of diagnostic services for the IVD market. These laboratories play a vital role in providing analysis of a wide range of disorders and diseases including pathology, immunology, cholesterol testing, allergy testing, urinalysis, genetic testing and many more. Kalorama Information’s Clinical Laboratory Services Market, 8th Edition is your comprehensive resource for insights…

$4,000.00 – $6,000.00

Cell Therapy and Gene Therapy Disease Markets, 2023-2029

April 30, 2024

Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…

$5,000.00 – $7,875.00

Clinical Laboratory Services Market, 8th Edition

$4,000.00 – $6,000.00

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

Explore the latest trends and developments in the in vitro diagnostic (IVD) market with Kalorama Information’s comprehensive report, In Vitro Diagnostic (IVD) Trends and Market Update: March 2024. Gain insights into key growth segments, industry trends, and emerging technologies shaping the future of IVD.

The report offers updated data analysis based on Kalorama Information’s annual…

$5,000.00 – $7,875.00

The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition

Explore the cutting-edge world of molecular point-of-care (mPOC) diagnostic solutions with our latest report, offering a detailed analysis of the market and future growth potential from 2023-2028. mPOC technology revolutionizes diagnostic capabilities, providing enhanced sensitivity and specificity compared to traditional near-patient tests. These solutions are instrumental in critical care units, physician offices, outpatient clinics,…

$5,000.00 – $7,875.00

Store

Cell Therapy and Gene Therapy Markets, 2021-2031

Table of Contents

all market reports

Related products

COVID-19 Testing Markets, 2023

Clinical Laboratory Services Market, 8th Edition

Cell Therapy and Gene Therapy Disease Markets, 2023-2029

Clinical Laboratory Services Market, 8th Edition

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition